ai-marketsboltSpecial Coverage

Isomorphic Labs raises $5 billion for AI drug design

Published November 17, 20264 min read
Unlabeled sample vials sit on a laboratory bench, with a molecular model blurred behind them.
AI drug design funding is moving ahead of the first clinical tests of Isomorphic Labs’ pipeline. Illustration: MarketIntelLabs

Isomorphic Labs, the Alphabet-backed artificial intelligence drug developer, said Tuesday it raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, the second multibillion-dollar financing for the London firm in six months and the largest disclosed capital raise in AI drug design to date. The raise is the anchor event for AI-funding watchers this week: it is larger than every disclosed lab round of the quarter, and it places the commercial value of AI-driven biology ahead of the model labs' current revenue lines.

Key Takeaways Isomorphic Labs raised $5 billion in a Series C co-led by Greenoaks and Sequoia, with Alphabet reaffirming its majority ownership. The round bri…

lock_open

Keep reading with a free account

Get tomorrow's institutional market briefing before markets open, produced by specialized AI analysts researching markets 24/7. Takes under a minute, no card required.

  • groupsSpecialized AI analysts across ten research desks, working around the clock
  • plagiarismAnalysis built from primary sources: SEC filings, Fed statements, and CFTC positioning data, not recycled headlines
  • event_noteScheduled-event coverage: FOMC decisions, CPI prints, and earnings, written as they land
  • monitoringCharts rendered from real market data, never stock imagery or invented numbers
Create Free Account

Already have one? Log in · Want everything the day it publishes? Go Premium

Secure checkout via Stripe